<DOC>
	<DOCNO>NCT01164709</DOCNO>
	<brief_summary>RATIONALE : Nelfinavir mesylate bortezomib may stop growth cancer cell block enzymes need cell growth . Bortezomib may also stop growth hematologic cancer block blood flow cancer . Giving nelfinavir mesylate together bortezomib may kill cancer cell . PURPOSE : This phase I trial study side effect best dose nelfinavir mesylate give together bortezomib treat patient relapse progressive advanced hematologic cancer .</brief_summary>
	<brief_title>Nelfinavir Mesylate Bortezomib Treating Patients With Relapsed Progressive Advanced Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - To assess safety nelfinavir mesylate combination bortezomib patient relapse progressive , advanced hematologic malignancy . - To establish phase II recommend dose nelfinavir mesylate patient . OUTLINE : This multicenter , dose-escalation study nelfinavir mesylate . Patients receive oral nelfinavir mesylate twice daily day 1-21 bortezomib IV day 8 , 11 , 15 , 18 course 1 . Course 1 duration 28 day . Beginning course 2 , patient receive oral nelfinavir mesylate twice daily day 1-14 bortezomib IV day 1 , 4 , 8 , 11 . Treatment repeat every 21 day 2 course . Patients respond disease may continue receive nelfinavir mesylate bortezomib 4 additional course . After completion study treatment , patient follow 30 day .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosed advanced hematologic malignancy meet follow criterion : Multiple myeloma Received ≥ 2 line prior chemotherapy ( induction chemotherapy follow highdose chemotherapy autologous stem cell transplant without maintenance therapy consider one line therapy ) Acute myeloid leukemia Acute lymphoblastic leukemia Diffuse large Bcell lymphoma Hodgkin lymphoma Mantle cell lymphoma Mature T NKcell neoplasms restrict follow WHOdefined entity : Tcell prolymphocytic leukemia Tcell large granular lymphocytic leukemia Aggressive NKcell leukemia Adult Tcell leukemia/lymphoma Extranodal NK/Tcell lymphoma ( nasal type ) Mycosis fungoides Sézary syndrome Primary CD30positive Tcell lymphoproliferative disorder Primary cutaneous anaplastic large cell lymphoma Primary cutaneous gammadelta Tcell lymphoma Peripheral Tcell lymphoma ( otherwise specify ) Angioimmunoblastic Tcell lymphoma Anaplastic large cell lymphoma ( ALKpositive/ALKnegative ) Grade 3B follicular lymphoma Relapsed follow progressed standard therapy Meeting follow criterion : Standard intensive therapy feasible Current disease state standard effective therapy Refused standard therapy curative option exist Measurable disease , define follow : Myeloma : measurable serum monoclonal protein &gt; 1 g/dL IgG , &gt; 0.5 g/dL IgA , IgM IgD , difference involve uninvolved free light chain level serum &gt; 100 mg/L Lymphoma : must ≥ 1 lesion measurable CT ( long diameter ≥ 15 mm ) Acute leukemia : ≥ 20 % blast bone marrow peripheral blood ( ≥ 200/mL blast peripheral blood ) No HIVassociated lymphoma PATIENT CHARACTERISTICS : WHO performance status 02 Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 75,000/mm³ ( bone marrow impairment , ≥ 20,000/mm^3 ) Hemoglobin &gt; 80 g/L ( consider cause underlying hematologic malignancy bone marrow impairment , &gt; 80 g/L transfusion ) Bilirubin ≤ 1.5 time upper limit normal ( ULN ) ( suspect hemolysis , direct bilirubin ≤ 1.5 time ULN ) ALT ≤ 2.5 time ULN Calculated creatinine clearance &gt; 30 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 12 month completion study treatment Willing capable comply oral regimen Capable understanding information give investigator trial Able adhere remain geographic proximity allow proper staging , treatment , followup No nonhematologic malignancy within past 5 year , except adequately treated cervical carcinoma situ localize nonmelanoma skin cancer No known chronic hepatitis B C infection know HIV infection No serious underlie medical condition ( judgment investigator ) would impair ability patient participate trial , include follow : Active autoimmune disease Uncontrolled diabetes Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric disorder No myocardial infarction within past 6 month No polyneuropathy &gt; grade 1 significantly interfering activity daily live painful polyneuropathy No known hypersensitivity trial drug hypersensitivity component trial drug PRIOR CONCURRENT THERAPY : See Disease Characteristics No 4 prior line chemotherapeutic regimen ( induction chemotherapy follow highdose chemotherapy autologous stem cell transplant without maintenance therapy consider one line therapy ) More 30 day since prior treatment clinical trial More 30 day since prior concurrent chemotherapy biologic agent For patient acute leukemia , hydroxyurea may give 48 hour first administration trial treatment , low dose cytarabine ( 20 mg/m^2 ) mitoxantrone 20 mg 14 day first dose At least 1 week since prior concurrent CYP3A4 modulators No concurrent experimental drug No concurrent radiotherapy No concurrent antineoplastic therapy chemotherapeutic biologic agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>peripheral T-cell lymphoma</keyword>
	<keyword>T-cell large granular lymphocyte leukemia</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>aggressive NK-cell leukemia</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>prolymphocytic leukemia</keyword>
</DOC>